Lilly’s Retevmo outperforms in trials for RET fusion-positive NSCLC and RET-mutant MTC

Pallavi Madhiraju- October 24, 2023 0

Eli Lilly (Lilly) has disclosed the results from two pivotal Phase 3 studies, LIBRETTO-431 and LIBRETTO-531, evaluating the efficacy of Retevmo in treating patients with ... Read More

Phase 3 LIBRETTO-531 trial : Lilly’s Retevmo meets primary endpoint of PFS

Pallavi Madhiraju- August 24, 2023 0

Eli Lilly and Company (NYSE: LLY) unveiled exceptional results from their LIBRETTO-531 study of Retevmo (selpercatinib), setting a new standard in the treatment of advanced ... Read More

LIBRETTO-431 study: Lilly’s Retevmo emerges as potential first-line treatment for RET fusion-positive NSCLC

Pallavi Madhiraju- August 6, 2023 0

Eli Lilly and Company (NYSE: LLY) has unveiled top-line results from the LIBRETTO-431 study, which focused on the assessment of Retevmo against platinum-based chemotherapy plus ... Read More

Selpercatinib FDA approval : Lilly’s therapy approved for treatment of lung and thyroid cancers with RET alteration

pharmanewsdaily- May 9, 2020 0

Selpercatinib FDA approval : The US Food and Drug Administration (FDA) has approved Eli Lilly and Company's Retevmo (selpercatinib) capsules for the treatment of three ... Read More

Lilly bags Retevmo FDA approval for RET-driven lung and thyroid cancers

pharmanewsdaily- May 9, 2020 0

Retevmo FDA approval : Eli Lilly and Company (Lilly) has secured approval from the US Food and Drug Administration (FDA) for Retevmo (selpercatinib, 40mg and ... Read More